Entity

Time filter

Source Type


Mnafgui K.,University of Sfax | Hajji R.,Hospital of Sidi Bouzid | Derbali F.,Hospital of Sidi Bouzid | Gammoudi A.,Hospital of Sidi Bouzid | And 5 more authors.
Cardiovascular Toxicology | Year: 2015

This study aimed to evaluate the antithrombotic, anti-inflammatory and anti-cardiac remodeling properties of eugenol in isoproterenol-induced myocardial infarction in rats. Male Wistar rats were randomly divided into four groups, control, iso [100 mg/kg body weight was injected subcutaneously into rats at an interval of 24 h for 2 days (6th and 7th day) to induce MI] and pretreated animals with clopidogrel (0.2 mg/kg) and eugenol (50 mg/kg) orally for 7 days and intoxicated with isoproterenol (Iso + Clop) and (Iso + EG) groups. Isoproterenol-induced myocardial infarcted rats showed notable changes in the ECG pattern, increase in heart weight index, deterioration in the hemodynamic function and rise in plasma level of troponin-T, CK-MB and LDH and ALT by 316, 74, 172 and 45 %, respectively, with histological myocardium necrosis and cells inflammatory infiltration. In addition, significant increases in plasma levels of inflammatory biomarkers such as fibrinogen, α1, α2, β1, β2 and γ globulins with decrease level of albumin were observed in infarcted rats as compared to normal ones. Else, the angiotensin-converting enzyme (ACE) activity in plasma, kidney and heart of the isoproterenol-induced rats was significantly increased by 34, 47 and 93 %, respectively, as compared to normal group. However, the administration of eugenol induced a clear improvement in cardiac biomarkers injury, reduced inflammatory mediators proteins, increased heart activities of superoxide dismutase and glutathione peroxidase with reduce in thiobarbituric acid-reactive substances content and inhibition of ventricular remodeling process through inhibition of ACE activity. Overall, eugenol evidences high preventive effects from cardiac remodeling process. © 2015 Springer Science+Business Media New York Source


Bauer S.,Center Hospitalier General Saint Jean | Pont A.,Center Hospitalier Intercommunal Robert Ballanger | Jaouen C.,Center Hospitalier General Saint Jean | Lecante V.,Center Hospitalier Intercommunal Andre Gregoire
Pharmacien Hospitalier et Clinicien | Year: 2014

Introduction The traceability of implantable medical device (IMD) is statutory (decree No. 2006-1497 of 29th November 2006) and must meet several objectives: traceability for sterility and/or contamination, financial traceability, adherence to the guidelines of therapeutic use. The aim of this study is to focus on key points of the tracking of IMD in three hospitals (A, B and C), and persistent difficulties. Materials and methods Quality indicators have been determinated by the descriptive study of three circuits of traceability of IMD. We could think about improvement points, with a review of the literature. Results The use of a computerized tracking of the IMD is the mean to keep safe the circuit in these three hospitals. Traceability rates are 90% (C) and 100% (A and B). The guideline of therapeutic use is respected in two hospitals. The more the staff is important (number and time spent) and trained, the better the traceability is. The hospital A avoided a loss of 99,000 euros while the hospital C lost 9900 euros. Discussion These hospitals are confronted to several difficulties with the use of a computerized tracking circuit. Staff implication (pharmacy, computer department and operating room department), softwares, non-harmonized identification systems of IMD are essentials points that must be taken into account in quality of tracking of IMD. We think that a national study, with the same quality indicators, should help hospitals improve their tracking of IMD. © 2013 Elsevier Masson SAS. Source


The accident and emergency department is a place where female victims of domestic abuse may arrive with various symptoms. The systematic screening of female victims was studied and implemented by an A&E team in the Paris region and has now been extended to all the hospital's departments where female victims may arrive for treatment. © 2014 Elsevier Masson SAS. All rights reserved. Source


Mnafgui K.,University of Sfax | Hajji R.,Hospital of Sidi Bouzid | Derbali F.,Hospital of Sidi Bouzid | Khlif I.,University of Sfax | And 5 more authors.
Cardiovascular Toxicology | Year: 2016

The present study aimed to investigate the cardioprotective effect of hydroxytyrosol (HT) against isoproterenol-induced myocardial infarction in rats. Male rats were randomly divided into four groups, control, isoproterenol (Isop) and pretreated animals with HT in two different doses (2 and 5 mg/kg) orally for 7 days and intoxicated with isoproterenol (Isop + HT1) and (Isop + HT2) groups. Myocardial infarction in rats was induced subcutaneously by isoproterenol (100 mg/kg, s.c.) at an interval of 24 h on 6th and 7th day. On 8th day, electrocardiographic (ECG) pattern, gravimetric and biochemical parameters were assessed. Isoproterenol exhibited changes in ECG pattern, including significant ST-segment elevation and increase in the serum troponin-T level by 317 % as compared to control rats. Moreover, cardiac injury markers (creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase) underwent a notable rise in serum of infarcted animals. Else, a disturbance in lipids profile and significant increase in lipase and angiotensin-converting enzyme (ACE) activities and heart weight ratio were observed in isoproterenol group. However, pre- and co-treatment with HT (2 and 5 mg/kg) improved the myocardium injury, restored the hemodynamic function and inhibited the ACE activity that prevent cardiac hypertrophy and remodeling. Overall, these findings demonstrated that HT exerted a potent cardioprotective effect against isoproterenol-induced myocardial infarction. © 2015, Springer Science+Business Media New York. Source


Mnafgui K.,University of Sfax | Hajji R.,Hospital of Sidi Bouzid | Derbali F.,Hospital of Sidi Bouzid | Khlif I.,University of Sfax | And 5 more authors.
Cardiovascular Toxicology | Year: 2015

The present study aimed to investigate the cardioprotective effect of hydroxytyrosol (HT) against isoproterenol-induced myocardial infarction in rats. Male rats were randomly divided into four groups, control, isoproterenol (Isop) and pretreated animals with HT in two different doses (2 and 5 mg/kg) orally for 7 days and intoxicated with isoproterenol (Isop + HT1) and (Isop + HT2) groups. Myocardial infarction in rats was induced subcutaneously by isoproterenol (100 mg/kg, s.c.) at an interval of 24 h on 6th and 7th day. On 8th day, electrocardiographic (ECG) pattern, gravimetric and biochemical parameters were assessed. Isoproterenol exhibited changes in ECG pattern, including significant ST-segment elevation and increase in the serum troponin-T level by 317 % as compared to control rats. Moreover, cardiac injury markers (creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase) underwent a notable rise in serum of infarcted animals. Else, a disturbance in lipids profile and significant increase in lipase and angiotensin-converting enzyme (ACE) activities and heart weight ratio were observed in isoproterenol group. However, pre- and co-treatment with HT (2 and 5 mg/kg) improved the myocardium injury, restored the hemodynamic function and inhibited the ACE activity that prevent cardiac hypertrophy and remodeling. Overall, these findings demonstrated that HT exerted a potent cardioprotective effect against isoproterenol-induced myocardial infarction. © 2015 Springer Science+Business Media New York Source

Discover hidden collaborations